COMMUNIQUÉS West-GlobeNewswire

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
02/09/2025
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an [...]
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
02/09/2025
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development [...]
Stereotaxis to Present at Upcoming Investor Conferences
02/09/2025
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and [...]
Highridge Medical Acquires Innovative Products from Accelus to Expand Capabilities in Spine Surgery
02/09/2025
Deal adds innovative expandable cage and other implant technology to the Highridge portfolio. WESTMINSTER, Colo., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Highridge Medical, one of the world’s largest privately held spine [...]
RAPPEL – La Fondation du Microbiote de Biocodex invite les universitaires et scientifiques canadiens à soumettre leur candidature pour une bourse de recherche de 35 000 €
02/09/2025
L’objectif est de faire progresser l’étude du rôle du microbiote sur la santé et les maladies humaines MONTRÉAL, 02 sept. 2025 (GLOBE NEWSWIRE) -- La Fondation du Microbiote de Biocodex , une organisation fondée par [...]
REMINDER – Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 research grant
02/09/2025
The objective is to advance microbiota’s role study in human health & diseases MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to [...]
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will [...]
PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH NUPSALA LIMITED
02/09/2025
MINNEAPOLIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) ( collectively referred to herein as "PetVivo"), is an [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
02/09/2025
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for [...]
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
02/09/2025
The new 5-year strategy, Impact4 , will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to [...]
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
02/09/2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
Hemex expands Global Clinical Network Alliance to strengthen end-to-end CRO Capabilities
02/09/2025
A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studies Comprehensive access to international [...]
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
02/09/2025
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective [...]
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
02/09/2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
02/09/2025
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above [...]
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
02/09/2025
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior [...]
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
02/09/2025
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company [...]

Pages